Skip to content
Menu

HC Wainwright & Co. Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $40

Benzinga Newsdesk 4 weeks ago

Analyst RatingsNewsInitiationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

HC Wainwright & Co. initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $40.

HC Wainwright & Co. initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $40.

Read at benzinga.com